American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
May 12, 2022
Earnings Call Speaker Segments
Stephanie Prince
executiveThanks, Matt, and I appreciate all of you being with us today. Ahead of handing things off to management, I'd like to offer a few comments regarding forward-looking statements. Please be aware that any remarks made during this call about the company's future expectations, plans and prospects qualify as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Results in reality could differ materially from what those forward-looking statements suggest, owing to a number of important factors, among them the ones covered in the company's SEC filings. Those include the annual report on Form 10-K covering the year that ended December 31, 2021, along with the definitive proxy statement for the Annual Meeting of Shareholders scheduled for June 21, 2022. No obligation is undertaken by the company to update any information in this conference call. At this point, I'd like to hand the conference over to Ray Stachowiak, CEO of AMS. Ray?
Ray Stachowiak
executiveThanks, Stephanie. Hello, everyone, and good afternoon. We appreciate you being with us today for the conference call covering our earnings for the first quarter of 2022. I'll start things off with a few comments, and after that I'll hand things over to Alexis Wallace, who serves as our Chief Accounting Officer, to walk through the financials. Craig Tagawa, who is our President, COO and CFO, will follow with a look at how operations performed during the results. Once those prepared remarks are done, we'll take your questions. AMS kicked off the new year strongly. Total revenue came in at $4.8 million, which represents an 11% rise period-over-period. That figure is roughly 3% above the $4.7 million reported for the fourth quarter just past, which stood as 2021's highest revenue quarter. During this first quarter, procedure volumes recovered for both proton beam therapy and Gamma Knife. Margins got a boost from lower operating costs, though that was partly offset by higher selling and administrative costs tied to chasing new business opportunities. Net income for first quarter 2022 reached $269,000, or $0.04 per diluted share, which adds to the net income of $219,000, or also $0.04 per diluted share, that we reported in the fourth quarter of 2021. In our view, this provides an excellent foundation for future growth and sustained profitability. After the quarter closed, we announced our third international location, which will be situated in Puebla, Mexico. That region is home to six million people and sits 80 miles from Mexico City. We're eager to get underway on this radiation therapy center joint venture, which will feature the state-of-the-art linear accelerator offering multiple treatment techniques, among them IMRT, VMAT, SBRT and radiosurgery. Startup of operations is anticipated in early 2023, subject to licensing and regulatory approvals. More recently, we announced that the company's sales team had been expanded through the hiring of Tim Keel as our Vice President of Sales and Marketing. Tim will oversee sales and marketing company-wide. Ernie Bates will serve as our Vice President of International Sales and Marketing. Tim brings more than 30 years of experience in the health care finance sector, and Craig and I have known him for at least 25 years. Throughout his career, Tim has occupied several senior sales roles at leading financial firms such as Bank of America, Citibank and KeyBanc, with a focus in project finance in oncology, outpatient surgery and diagnostic imaging. With the pandemic waning, now is an excellent moment to leverage Tim's relationships with hospitals, medical development entrepreneurs and medical equipment vendors and bring attention to AMS' expanded resources and our capabilities. We're delighted that Tim has joined us, and we look forward to his contributions. I'll now turn the call over to Alexis for the first quarter financial review. Alexis?
Alexis Wallace
executiveThanks, Ray. Good afternoon, everybody. Before I get into my prepared comments, please take a look at the first quarter 2022 earnings press release we put out earlier today. If you don't have one, you can find it on our site, ashs.com, under the Investors tab in Press Releases; so moving on to the first quarter results. For the three months ended March 31, 2022, revenue rose 11.1% to $4,847,000 versus $4,364,000 in the first quarter of 2021. Revenue from the proton therapy system the company has installed at Orlando Health in Florida climbed 33.2% to $2,039,000 in the first quarter, up from $1,531,000 in the first quarter of 2021. Total proton therapy fractions came to 1,628 in the first quarter, a 32.3% rise from 1,231 proton therapy fractions in the first quarter of 2021. Revenue from the company's Gamma Knives operations fell 2.9% to 2,808,000 in the first quarter of 2022, versus 2,892,000 in the first quarter of 2021. Gamma Knives procedures dropped by 7.3% to 329 in the first quarter of 2022 from 355 during the same period a year earlier. Gross margin for the first quarter of 2021 rose 44.01% to $2,067,000, or 42.06% of revenue, versus gross margin of $1,434,000, or 32.09% of revenue, in the first quarter of 2021. Selling and administrative costs rose by 21.7% to $1,319,000 for the three-month period, versus $1,084,000 during the same period a year earlier. Interest expense fell 43.1% to $148,000, versus $260,000 during the same period a year earlier. Operating income for the first quarter was $600,000, versus operating income of $90,000 in the first quarter of 2021, a rise of 566.7%. That increase reflects higher revenue along with lower total direct operating costs and depreciation expense. Income tax expense rose to $206,000 in the first quarter, versus $6,000 in the first quarter last year. The rise came from increased earnings during the current period, return to provision adjustments arising from foreign income tax returns filed during the current period and permanent domestic tax differences. The tax rate is expected to stay at the elevated level through the end of this year. Net income in the first quarter of 2022 was $269,000, or $0.04 per diluted share, versus net income of $29,000, or $0.00 per diluted share, in the first quarter of 2021. Fully diluted weighted average common shares outstanding were 6,299,000 and 6,322,000 for the first quarter of 2022 and 2021 respectively. Adjusted EBITDA, a non-GAAP financial measure, was $1,922,000 in the first quarter of 2022, versus $1,600,000 in the first quarter of 2021, a rise of 20.1%. At March 31, 2022, cash, cash equivalents and restricted cash was $8,401,000, versus $8,263,000 at December 31, 2021. Shareholders' equity at March 31, 2022 was $24,720,000, or $4.7 per outstanding share; that compares to shareholder's equity at December 31, 2021 of $24,239,000, or $4.1 per outstanding share. Craig, I'd like to hand things over to you now so we can go through the operational review for the first quarter. Craig?
Craig Tagawa
executiveThanks, Alexis. Good afternoon, everybody. As Alexis said, revenue for the first quarter came in at $4.8 million, up 11.1% versus the first quarter a year ago. That's a solid way to begin the year, and it extends the emerging pattern we saw starting in the fourth quarter, when revenue came in at $4.7 million — our biggest revenue quarter of 2021. In Florida, first quarter 2022 revenue for the proton therapy system rose 33.2% to $2 million on higher volumes. Total proton therapy fractions were up 32.3% to 1,628. That rebound largely reflected the weak first quarter last year caused by the pandemic, plus a full quarter without meaningful maintenance downtime following two straight quarters of intermittent downtime. Gamma Knife revenue fell 2.9% to $.2.8 million. The decline came from fewer procedures, partly offset by higher average reimbursement. That higher average reimbursement resulted from a rise in the average rate at the company's retail sites, driven by a favorable shift in pair mix toward more commercial payers. Even so, on a new metric, revenue for same centers in operation rose 7.2% versus those same centers in the equivalent period a year earlier. Gamma Knife procedures declined by 7.3% to 3,329 in the first quarter. That was mostly because two contracts expired, one in the first quarter of 2021 and one in the fourth quarter of 2021. Leaving out those two expired contracts, Gamma Knife volumes for same centers in operation were up 1.9% versus Gamma Knife volumes at those same centers in the equivalent period a year earlier. Gross margin rose 44.1% in dollars to $2.1 million. As a percentage, gross margin expanded 970 basis points to 42.6% of revenue, versus 32.9% in the first quarter of 2021. The gain was mainly attributable to a 16.6% drop in other direct operating costs stemming from the expiration of the two contracts I just mentioned. Selling and administrative cost rose 21.7% to $1.3 million versus last year's first quarter, driven by higher legal and related fees tied to new business opportunities such as the Puebla, Mexico project we announced recently. Interest expense fell 43.1% to $148,000, versus $260,000 in the equivalent period last year, reflecting the debt refinancing we finished in April, 2021, which sharply reduced the interest rate on the portfolio. Equally important, that refinancing boosted our liquidity by lowering our debt service payments and providing a $7 million line of credit. On top of that, our current ratio — defined as current assets over current liabilities — has risen to 3.2 times, versus 1.6 times at March 31, 2021. At our international locations, the Icon upgrade at Gamma Knife Center Ecuador is now slated for installation late this year. While we keep awaiting the regulatory approvals we need, it's going to be among just a handful of Gamma Knife icon units across South America. In addition, at the joint venture we announced recently in Puebla, Mexico, we'll be putting in a new linear accelerator once it launches in early 2023, subject to licensing and regulatory approvals. Our sales team's growth has us enthusiastic, and paired with the broader radiation therapy products we now offer, that should expand our new business pipeline along with the talks we hold with current and prospective customers regarding placements of advanced products; that wraps up the formal portion of what we presented. Matt, at this point we'd like to hand the call back over to you and begin taking questions.
Tony Kamin
analystHello. I joined this call late, so I didn't catch the opening minutes. If I repeat something you've covered already, my apologies. We had a strong quarter, and I think my question is fairly straightforward — the proton beam performed really well. During that quarter, it accounted for more than 40% of your revenue from a single machine, compared to — I don't know the exact count — all your Gamma Knives combined. So here's what I want to know: you've brought on an additional salesperson. You presumably have a very satisfied client who can serve as a reference, plus years of experience in this space. Over the past several years, the thinking seemed to be that these systems cost too much, that interest rates were so low that buyers would self-finance, and then COVID hit. What I'm really asking, I suppose, is whether you believe you'll eventually be in a position to place additional proton beams? And related to that, I'm also wondering whether anything on the clinical study side has shifted in a way that makes hospitals lose interest in these systems altogether?
Ray Stachowiak
executiveTony, thanks for those questions. Regarding the technology, it remains highly relevant and attractive to healthcare systems that aim to lead in cancer treatment through radiation. We're quite active and stay active. I'd say we've increased our efforts in chasing additional proton beam business. Nothing would please us more than being able to make an announcement of that kind at some point down the road. With the larger sales team we now have, we possess the ability to go after that business, and we definitely have the financial and economic wherewithal to chase it. That isn't holding us back the way it might have previously. Also, what we offer continues to be persuasive to healthcare systems. Our pitch goes something like this: a lot of healthcare systems might have $100 million in capital expenditure requests or capital wants or needs or desires, yet only $25 million available in their capital budget. We can assist in stretching that capital budget and securing the technology that the clinicians and strategic thinkers at that healthcare system want, provided they aspire to be a leading provider of cancer treatment using radiation. So I believe our argument remains very persuasive. We have the economic and financial resources, and we're expanding our human resource capabilities to go after that business.
Tony Kamin
analystAlso, did I get it right that, in your view, the client you have right now is pleased with the way the existing proton beam is performing?
Ray Stachowiak
executiveYeah, I'd say they're extremely pleased — we'd have no problem, in fact we'd be glad, to point to them as a reference as we go after new proton beam business. My sense is they'll be very pleased and give us a really strong reference.
Tony Kamin
analystAll right, and I suppose the final thing I'll ask about this subject, looking at it from the maker's side, they've got to realize how gradually these units have been selling. Do you get any impression that producers are now more willing to collaborate with you on putting together an offering that suits everybody, so that more systems get sold?
Ray Stachowiak
executiveWithout a doubt. And I want to make clear that our doors are open a bit wider to any builder of proton beam equipment. Mevion and us go back a long way, and as far as I'm concerned, that remains a solid partnership; however, should a client show up wanting a proton beam system made by a different company, nothing restricts us to a single supplier of such systems. That's why we're going after this market with something like an "open ears, open eye" approach, hearing out whatever the market and the customer want. Still, yes, we'll also connect with the OEMs.
Tony Kamin
analystNo, that's reassuring to hear; and clearly, even just the boost from a few additional proton beams on American Shared's valuation would be enormously disproportionate, but best of luck with that. Once more, I may have overlooked this during the opening, but could you speak a bit about the broader product line offerings that Craig brought up? And in particular, with some sense of where you see — or what you see in that wider lineup that might potentially have the greatest impact?
Ray Stachowiak
executiveSure. Thanks once more, Tony, for your question. When you look at the equipment holdings in our portfolio, there are 14 Gamma Knives made by Elekta, plus a single proton beam system made by Mevion. In the marketplace there exist numerous makes and models of what I'd refer to as radiation therapy equipment that treats cancer using radiation. A linear accelerator is one such device, and those linear accelerators — those LINACs — are available in a wide range of makes and models, priced from, let's say, $3 million up to perhaps $7 million. And we've broadened our product offerings so that linear accelerators are now included. Our offerings now also include MR/LINACs, another type of equipment that treats cancer using radiation and that relies on an MR system for treatment planning purposes. So any type of equipment that treats cancer with radiation therapy — with radiation therapy is part of our product bag. And the recent joint venture we announced in Puebla, Mexico is likely the finest illustration of how our broadened product offering generated that opportunity; what we're installing in Puebla isn't an Elekta Gamma Knife or a proton beam system. What we're installing is a linear accelerator made by Elekta, though it's a very high-end linear accelerator that will treat — have a wide variety of treatment options available for that population of six million.
Tony Kamin
analystI'm sorry,
Ray Stachowiak
executiveIs that helpful, Tony?
Tony Kamin
analystYeah, that really helps a lot. I'm pretty thrilled about all of it, and about you bringing on another salesperson to grow that. Best of luck with it. Thanks.
Ray Stachowiak
executiveAll right. Thanks, Tony.
Ray Stachowiak
executiveThanks, Matt. And thanks to all of you for being with us today. To sum things up, I want to note that for the first quarter of 2022, we posted earnings per share of $0.04; in the fourth quarter of 2021, we likewise posted earnings of $0.04 a share. Given this foundation for the business, our view is that AMS is headed toward profitability that can be sustained. We can't wait to talk with you once more on our second quarter call in mid-August. If anything comes up before then, please reach out to us directly. Be well, and stay safe. Goodbye.
Operator
operatorThat brings this conference to a close. We appreciate your joining today's presentation. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.